158
Spero Therapeutics, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
114
FY23:
131
FY24:
107
FY25:
67.3
(positive)
Change from FY21 to FY25
millions USD
FY21:
13.2
FY22:
11.2
FY23:
51.2
FY24:
3.27
FY25:
1.63
Total assets
Change from FY21 to FY25
millions USD
FY21:
171
FY22:
125
FY23:
182
FY24:
111
FY25:
68.9
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
18.7
FY22:
21.6
FY23:
37.2
FY24:
49.1
FY25:
8.87
(negative)
Change from FY21 to FY25
millions USD
FY21:
64.1
FY22:
27.2
FY23:
38.3
FY24:
15.3
FY25:
1.03
(positive)
Change from FY21 to FY25
millions USD
FY21:
88.3
FY22:
75.9
FY23:
107
FY24:
46.1
FY25:
59.0
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
171
FY22:
125
FY23:
182
FY24:
111
FY25:
68.9
All amounts in millions USD